{"id":65215,"date":"2026-06-17T20:39:11","date_gmt":"2026-06-17T20:39:11","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/65215\/"},"modified":"2026-06-17T20:39:11","modified_gmt":"2026-06-17T20:39:11","slug":"astrazeneca-azn-advances-oral-glp-1-receptor-agonist-elecoglipron-to-phase-iii-trials","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/65215\/","title":{"rendered":"AstraZeneca (AZN) Advances Oral GLP-1 Receptor Agonist Elecoglipron to Phase III Trials"},"content":{"rendered":"\n

AstraZeneca (NYSE:AZN<\/a>) is one of the 12 Best Growth Stocks Trading in Oversold Territory<\/a>. On June 8, AstraZeneca\u2019s oral GLP-1 receptor agonist, elecoglipron, is advancing to a Phase III clinical program following positive results from the VISTA and SOLSTICE Phase IIb trials. In the VISTA study, adults with obesity or overweight achieved 11.8% weight loss at 36 weeks, while the SOLSTICE trial showed a 1.9% reduction in HbA1c for adults with type 2 diabetes at 26 weeks.<\/p>\n

The safety profile for the drug was consistent with the GLP-1 class, with mostly mild to moderate gastrointestinal adverse events reported. AstraZeneca (NYSE:AZN) noted that the Phase II data will help optimize the dose escalation schedule for the upcoming Phase III studies, which are designed to further enhance tolerability for patients.<\/p>\n

\"AstraZeneca AstraZeneca (AZN) Advances Oral GLP-1 Receptor Agonist Elecoglipron to Phase III Trials <\/p>\n

Pixabay\/Public Domain<\/p>\n

The expanded Phase III program includes the EMBOLD and ELUMINATE trials, which will evaluate elecoglipron as both a monotherapy and in combination with other treatments. These trials aim to address the complex nature of obesity and type 2 diabetes while investigating the drug\u2019s long-term cardiovascular and kidney health outcomes.<\/p>\n

AstraZeneca (NYSE:AZN) is a global biopharmaceutical company headquartered in Cambridge, focused on oncology. It develops a broad portfolio of cancer treatments targeting lung, breast, ovarian, and blood cancers, aiming to advance science-led therapies across multiple platforms.<\/p>\n

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/a>.<\/p>\n

READ NEXT:\u00a033 Stocks That Should Double in 3 Years<\/a> and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy<\/a>.\u00a0<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"AstraZeneca (NYSE:AZN) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 8, AstraZeneca\u2019s…\n","protected":false},"author":2,"featured_media":65216,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,30794,30796,30795,13670],"class_list":["post-65215","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-glp-1-receptor-agonist","tag-oversold-territory","tag-phase-iii","tag-type-2-diabetes"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116767383133220029","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/65215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=65215"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/65215\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/65216"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=65215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=65215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=65215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}